HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Morphine glucuronidation in preterm neonates, infants and children younger than 3 years.

AbstractBACKGROUND AND OBJECTIVE:
A considerable amount of drug use in children is still unlicensed or off-label. In order to derive rational dosing schemes, the influence of aging on glucuronidation capacity in newborns, including preterms, infants and children under the age of 3 years was studied using morphine and its major metabolites as a model drug.
METHODS:
A population pharmacokinetic model was developed with the nonlinear mixed-effects modelling software NONMEM V, on the basis of 2159 concentrations of morphine and its glucuronides from 248 infants receiving intravenous morphine ranging in bodyweight from 500 g to 18 kg (median 2.8 kg). The model was internally validated using normalized prediction distribution errors.
RESULTS:
Formation clearances of morphine to its glucuronides and elimination clearances of the glucuronides were found to be primarily influenced by bodyweight, which was parameterized using an allometric equation with an estimated exponential scaling factor of 1.44. Additionally, a postnatal age of less than 10 days was identified as a covariate for formation clearance to the glucuronides, independent of birthweight or postmenstrual age. Distribution volumes scaled linearly with bodyweight.
CONCLUSIONS:
Model-based simulations show that in newborns, including preterms, infants and children under the age of 3 years, a loading dose in microg/kg and a maintenance dose expressed in microg/kg1.5/h, with a 50% reduction of the maintenance dose in newborns younger than 10 days, results in a narrow range of morphine and metabolite serum concentrations throughout the studied age range. Future pharmacodynamic investigations are needed to reveal target concentrations in this population, after which final dosing recommendations can be made.
AuthorsCatherijne A J Knibbe, Elke H J Krekels, Johannes N van den Anker, Joost DeJongh, Gijs W E Santen, Monique van Dijk, Sinno H P Simons, Richard A van Lingen, Evelyne M Jacqz-Aigrain, Meindert Danhof, Dick Tibboel
JournalClinical pharmacokinetics (Clin Pharmacokinet) Vol. 48 Issue 6 Pg. 371-85 ( 2009) ISSN: 1179-1926 [Electronic] Switzerland
PMID19650676 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Glucuronides
  • Morphine
  • UGT2B7 protein, human
  • Glucuronosyltransferase
Topics
  • Age Factors
  • Child, Preschool
  • Female
  • Glucuronides (metabolism)
  • Glucuronosyltransferase (metabolism)
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature (metabolism)
  • Male
  • Metabolic Clearance Rate (physiology)
  • Morphine (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: